autologous cd34+ cells transduced withpsrs11.efs.il2rg.pre

Cell therapyexperimental

Clinical trial activity

8 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Jan 1, 1996 (NCT00058773)

Timeline

1990s

  1. Jan 1, 1996

    Earliest Phase 1 Sponsor(trial)

2000s

  1. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetTissue restoration

    tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • autologous cd34+ cells transduced withpsrs11.efs.il2rg.pre
  • autologous ebv specific ctl
  • ebv specific cytotoxic t-lymphocytes
  • ebv-specific cytotoxic t lymphocytes

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06391814N/AJan 16, 2024Ciusss de L'Est de l'Île de Montréal
NCT03988582Phase 2Jun 11, 2019Memorial Sloan-Kettering Cancer Center
NCT03283826Phase 1Oct 19, 2017Atara Biotherapeutics
NCT02677688Phase 1/Phase 2 (Phase 2)Jan 1, 2016University of Nantes
NCT01175239Phase 1/Phase 2 (Phase 2)Apr 1, 2011University of London
NCT00953420Phase 2Nov 1, 2009Baylor University, Methodist Cancer Center, Houston, Texas, University of Texas at Houston
NCT00609219Phase 1Aug 1, 2001Baylor University, Methodist Cancer Center, Houston, Texas
NCT00058773Phase 1Jan 1, 1996Baylor University, Methodist Cancer Center, Houston, Texas
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Baylor UniversityAcademic/Hospital3321996
Methodist Cancer Center, Houston, TexasAcademic/Hospital3021996
Atara BiotherapeuticsFor profit1112017
Ciusss de L'Est de l'Île de MontréalAcademic/Hospital1112024
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital1112019
University of LondonAcademic/Hospital1112011
University of NantesAcademic/Hospital1112016
University of Texas at HoustonAcademic/Hospital1012009
8 organizations
Page 1 / 1